{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458622631
| drug_name = 
| IUPAC_name = 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
| image = Dacarbazine.svg
| width = 175

<!--Clinical data-->
| pronounce = {{IPAc-en|d|ə|ˈ|k|ɑr|b|ə|ˌ|z|iː|n}}
| tradename = DTIC-Dome, others
| Drugs.com = {{drugs.com|monograph|dacarbazine}}
| MedlinePlus = a682750
| pregnancy_US = C
| legal_status = Rx-only
| routes_of_administration = [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability = 100% (IV)
| metabolism = Extensive
| metabolites =
| elimination_half-life = 5 hours
| excretion = [[Kidney]] (40% as unchanged dacarbazine)

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 4342-03-4
| ATC_prefix = L01
| ATC_suffix = AX04
| PubChem = 2942
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 4305
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00851
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10481959
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7GR28W0FJI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C06936
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 476

<!--Chemical data-->
| C=6 | H=10 | N=6 | O=1
| molecular_weight = 182.18 g/mol
| smiles = CN(C)/N=N/c1ncnc1C(N)=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FDKXTQMXEQVLRF-ZHACJKMWSA-N
}}
<!-- Definition and medical uses -->
'''Dacarbazine''' ('''DTIC'''), also known as '''imidazole carboxamide''', is a [[chemotherapy medication]] used in the treatment of [[melanoma]] and [[Hodgkin's lymphoma]].<ref name=AHFS2016/> For Hodgkin's it is often used together with [[vinblastine]], [[bleomycin]], and [[doxorubicin]].<ref name=AHFS2016/> It is given by [[intravenous|injection into a vein]].<ref name=AHFS2016>{{cite web|title=Dacarbazine|url=https://www.drugs.com/monograph/dacarbazine.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20170911000000/http://www.drugs.com/monograph/dacarbazine.html|archivedate=11 September 2017|df=}}</ref>

<!-- Side effects and mechanism -->
Common side effects include loss of appetite, vomiting, [[leukopenia|low white blood cell count]], and [[low platelets]].<ref name=AHFS2016/> Other serious side effects include [[liver problems]] and [[allergic reactions]].<ref name=AHFS2016/> It is unclear if use in [[pregnancy]] is safe for the baby.<ref name=AHFS2016/> Dacarbazine is in the [[alkylating antineoplastic agent|alkylating agent]] and [[purine analog]] families of medication.<ref name=AHFS2016/>

<!-- History and culture -->
Dacarbazine was approved for medical use in the United States in 1975.<ref name=AHFS2016/> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> The wholesale cost in the [[developing world]] is about 7.45 to 18.24 USD per 200&nbsp;mg vial.<ref name=ERC2014>{{cite web|title=Dacarbazine|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=DCR200A&s_year=2014&year=2014&str=200%20mg&desc=Dacarbazine&pack=new&frm=VIAL&rte=INJ&class_code2=08%2E2%2E&supplement=&class_name=%2808%2E2%2E%29Cytotoxic%20and%20adjuvant%20medicines%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}</ref> In the United Kingdom this dose costs the [[NHS]] about 7.50 pounds.<ref name=BNF69>{{cite book|title=British national formulary : BNF 69|date=2015|publisher=British Medical Association|isbn=9780857111562|page=600|edition=69}}</ref>

==Medical uses==
As of mid-2006, dacarbazine is commonly used as a single agent in the treatment of [[metastasis|metastatic]] [[melanoma]],<ref>{{cite journal|last1=Serrone|first1=L|last2=Zeuli|first2=M|last3=Sega|first3=FM|last4=Cognetti|first4=F|title=Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.|journal=Journal of experimental & clinical cancer research : CR|date=March 2000|volume=19|issue=1|pages=21–34|pmid=10840932}}</ref><ref>{{cite journal|last1=Bhatia|first1=S|last2=Tykodi|first2=SS|last3=Thompson|first3=JA|title=Treatment of metastatic melanoma: an overview.|journal=Oncology (Williston Park, N.Y.)|date=May 2009|volume=23|issue=6|pages=488–96|pmid=19544689|pmc=2737459}}</ref> and as part of the [[ABVD]] [[chemotherapy regimen]] to treat [[Hodgkin's lymphoma]],<ref>{{cite journal|last1=Rueda Domínguez|first1=A|last2=Márquez|first2=A|last3=Gumá|first3=J|last4=Llanos|first4=M|last5=Herrero|first5=J|last6=de Las Nieves|first6=MA|last7=Miramón|first7=J|last8=Alba|first8=E|title=Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study.|journal=Annals of Oncology|date=December 2004|volume=15|issue=12|pages=1798–804|pmid=15550585|doi=10.1093/annonc/mdh465}}</ref> and in the MAID regimen for sarcoma.<ref>{{cite journal|last1=Elias|first1=A|last2=Ryan|first2=L|last3=Aisner|first3=J|last4=Antman|first4=KH|title=Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.|journal=Seminars in oncology|date=April 1990|volume=17|issue=2 Suppl 4|pages=41–9|pmid=2110385}}</ref><ref>{{cite journal|last1=Pearl|first1=ML|last2=Inagami|first2=M|last3=McCauley|first3=DL|last4=Valea|first4=FA|last5=Chalas|first5=E|last6=Fischer|first6=M|title=Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.|journal=International Journal of Gynecological Cancer |date=2001|volume=12|issue=6|pages=745–8|pmid=12445253|doi=10.1046/j.1525-1438.2002.01139.x}}</ref> Dacarbazine was proven to be just as efficacious as procarbazine<ref>{{cite journal|last1=Jelić|first1=S|last2=Babovic|first2=N|last3=Kovcin|first3=V|last4=Milicevic|first4=N|last5=Milanovic|first5=N|last6=Popov|first6=I|last7=Radosavljevic|first7=D|title=Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.|journal=Melanoma research|date=February 2002|volume=12|issue=1|pages=91–8|pmid=11828263|doi=10.1097/00008390-200202000-00013}}</ref> in the German trial for paediatric Hodgkin's lymphoma, without the teratogenic effects.{{citation needed|date=August 2016}} Thus COPDAC has replaced the former COPP regime in children for TG2 & 3 following OEPA.<ref>{{cite journal|last1=Mauz-Körholz|first1=C|last2=Hasenclever|first2=D|last3=Dörffel|first3=W|last4=Ruschke|first4=K|last5=Pelz|first5=T|last6=Voigt|first6=A|last7=Stiefel|first7=M|last8=Winkler|first8=M|last9=Vilser|first9=C|last10=Dieckmann|first10=K|last11=Karlén|first11=J|last12=Bergsträsser|first12=E|last13=Fosså|first13=A|last14=Mann|first14=G|last15=Hummel|first15=M|last16=Klapper|first16=W|last17=Stein|first17=H|last18=Vordermark|first18=D|last19=Kluge|first19=R|last20=Körholz|first20=D|title=Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.|journal=Journal of Clinical Oncology|date=10 August 2010|volume=28|issue=23|pages=3680–6|pmid=20625128|url=http://jco.ascopubs.org/content/28/23/3680.full|doi=10.1200/jco.2009.26.9381|deadurl=no|archiveurl=https://web.archive.org/web/20160716050444/http://jco.ascopubs.org/content/28/23/3680.full|archivedate=16 July 2016|df=}}</ref>

==Side effects==
Like many chemotherapy drugs, dacarbazine may have numerous serious side effects, because it interferes with normal cell growth as well as cancer cell growth.  Among the most serious possible side effects are birth defects to children conceived or carried during treatment; sterility, possibly permanent; or immune suppression (reduced ability to fight infection or disease). Dacarbazine is considered to be highly [[Chemotherapy-induced nausea and vomiting|emetogenic]],<ref>{{cite journal|last1=Aoki|first1=S|last2=Iihara|first2=H|last3=Nishigaki|first3=M|last4=Imanishi|first4=Y|last5=Yamauchi|first5=K|last6=Ishihara|first6=M|last7=Kitaichi|first7=K|last8=Itoh|first8=Y|title=Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant.|journal=Molecular and clinical oncology|date=January 2013|volume=1|issue=1|pages=41–46|doi=10.3892/mco.2012.15|pmid=24649120|pmc=3956247}}</ref> and most patients will be pre-medicated with [[dexamethasone]] and antiemetic drugs like [[5-HT3 antagonist|5-HT<sub>3</sub> antagonist]] (e.g., [[ondansetron]]) and/or [[NK1 receptor antagonist|NK<sub>1</sub> receptor antagonist]] (e.g., [[aprepitant]]). Other significant side effects include headache, fatigue and occasionally diarrhea.

The Swedish National Board of Health and Welfare has sent out a [[Boxed warning|black box warning]] and suggests avoiding dacarbazine due to liver problems.<ref>{{cite web|url=http://www.fass.se/LIF/produktfakta/audit_page.jsp?_sourcePage%3D%2Fproduktfakta%2Fartikel_produkt.jsp%26docType%3D7%26nplId%3D19971212000080 |title=Archived copy |accessdate=August 19, 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20111001011425/http://www.fass.se/LIF/produktfakta/audit_page.jsp?_sourcePage=%2Fproduktfakta%2Fartikel_produkt.jsp&docType=7&nplId=19971212000080 |archivedate=October 1, 2011 }}</ref>

==Mechanism of action==
Dacarbazine works by methylating guanine at the O-6 and N-7 positions.<ref>{{cite journal|last1=Kewitz|first1=S|last2=Stiefel|first2=M|last3=Kramm|first3=CM|last4=Staege|first4=MS|title=Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells.|journal=Leukemia research|date=January 2014|volume=38|issue=1|pages=138–43|pmid=24284332|doi=10.1016/j.leukres.2013.11.001}}</ref> Guanine is one of the four nucleotides that makes up DNA. The methylated DNA strands stick together such that cell division becomes impossible. This affects cancer cells more than healthy cells because cancer cells divide faster. Unfortunately however, some of the healthy cells will still be damaged.

Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to [[diazomethane]], which is an alkylating agent.

==Synthesis==
[[File:Dacarbazine-synthesis.svg|thumb|512px|center|Shealy et al., J. Org. Chem. 27, 2150 (1962); Hano et al., Gann 59, 207 (1968), C.A. 69, 42527g (1968).]]

==History==
{{see also|History of cancer chemotherapy}}
Dacarbazine was developed by Y. Fulmer Shealy, PhD at Southern Research Institute in Birmingham, Alabama. Research was funded by a U.S. federal grant. Dacarbazine gained FDA approval in May 1975 as DTIC-Dome. The drug was initially marketed by [[Bayer]].

==Suppliers==
[[Bayer]] continues to supply DTIC-Dome. There are also [[Generic drug|generic]] versions of dacarbazine available from APP, Bedford, Mayne Pharma (now [[Hospira]]) and [[Teva Pharmaceutical Industries|Teva]].

==See also==
* [[Melanoma]]
* [[Hodgkin disease]]
* [[ABVD]]
* [[History of cancer chemotherapy]]
* [[Alkylating antineoplastic agent]]

==References==
{{Reflist}}

;Bibliography
{{refbegin|2}}
*MedLine, U.S. National Institutes of Health, National Library of Medicine,[http://www.nlm.nih.gov/medline/]
*Cancerweb,[http://cancerweb.ncl.ac.uk/cancerweb/]
*OncoLink,[https://web.archive.org/web/20051013065613/http://www.oncolink.upenn.edu/]
{{refend}}

{{Chemotherapeutic agents}}

[[Category:Hepatotoxins]]
[[Category:Imidazoles]]
[[Category:DNA replication inhibitors]]
[[Category:IARC Group 2B carcinogens]]
[[Category:Carboxamides]]
[[Category:Teratogens]]
[[Category:World Health Organization essential medicines]]
[[Category:Cancer treatments]]